Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing

Hamburg, Germany, 19 October 2020:
Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors. The funding will be used to advance the Company's proprietary pipeline based on the Topas Particle Conjugates technology platform.

For further information, please follow this link to the full version of Topas Therapeutics' press release.

TOP

Attachments

  • Original document
  • Permalink

Disclaimer

Evotec SE published this content on 19 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2020 09:14:03 UTC